Question 1

I am pre-revenue. Is it too early for a GTM diagnosis?

Accepted Answer

Pre-revenue is the best time for a GTM diagnosis, not because the problem is most visible at this stage, but because the cost of misdirection is lowest. A pre-revenue founder who discovers their ICP hypothesis is wrong spends nothing correcting it. A post-funding founder who discovers the same thing spends six months of runway correcting it. The GTM Clarity Assessment works from your current hypothesis alone. No pipeline data, no CRM, no outbound metrics required. It tells you whether the direction is right before you build a motion on top of it.

Question 2

I have a great product but nobody seems to want to buy it. What will this find that I have not already figured out?

Accepted Answer

The most common finding in this situation: the product is solving the right problem for the wrong buyer at the wrong moment. The product works. The use case is valid. But the ICP is defined by who could benefit rather than who has the urgency, the budget, and the authority to buy right now. The second most common finding: the message describes what the product does rather than what changes for the buyer when they use it. Buyers do not buy features. They buy the removal of a specific pain. When the message leads with features, it produces interest without urgency, and interest without urgency does not convert. What Wiremap adds that you have not already figured out: the pattern. You are inside your own situation. The diagnostic system has seen the same pattern across comparable companies and knows which intervention produces results in 30 days versus which requires a 90 day motion rebuild.

Question 3

I do not have much capital. Can I afford this?

Accepted Answer

The GTM Clarity Assessment is $499. The question is not whether you can afford $499. The question is whether you can afford the alternative. An SDR hire into an unvalidated motion costs $60,000 to $90,000 in salary before you know it is pointed in the wrong direction. A content and demand gen investment without validated positioning costs $24,000 to $60,000 before the feedback loop closes. The $499 diagnosis that tells you the direction is wrong before either of those decisions is the cheapest investment you will make this quarter. Introductory pricing exists specifically to make the diagnosis accessible at the stage when founders need it most and have the least capital to commit.

Question 4

What do I need to prepare before I start the intake form?

Accepted Answer

Less than you think. For the GTM Clarity Assessment: a description of your product and the problem it solves, your current ICP hypothesis even if informal, your website URL, any outreach copy you have run, a description of what you have tried and what happened, and the names of 2 to 3 competitors. Most founders complete this in a single 25 to 35 minute sitting. No spreadsheets, no CRM exports, no formal documentation required. The intake is designed to extract the diagnostic signal from wherever you currently are, not from where you wish you were. Partial information still produces useful findings.

Question 5

What does the report actually give me that I can use on Monday?

Accepted Answer

A specific action plan with three prioritised actions, sequenced in the order they need to happen, each with a named deliverable and a 30 day signal that tells you whether the action is working. Not a list of things to consider. A list of things to do, in order, starting Monday. The action plan is calibrated to what you can execute at your current stage without additional resources. If an action requires budget you do not have or a team member you have not hired, it does not appear in your plan. The plan is built for your actual situation, not the ideal one.

Question 6

My outbound team is active but pipeline is not growing. Is this an execution problem or a direction problem?

Accepted Answer

This is the central diagnostic question at growth stage and the one the GTM Risk Assessment is specifically built to answer. The distinction matters enormously because the interventions are completely different. A direction problem, which means wrong ICP, wrong message, or wrong channel, requires rebuilding the motion. An execution problem, which means low activity, poor follow-up, or weak discovery, requires coaching and process. Applying an execution solution to a direction problem produces a more efficiently broken motion. The specific signals that distinguish them: reply rate below 3% despite high volume almost always indicates direction. Reply rate above 3% but low conversion to meetings almost always indicates messaging. Meeting conversion above 30% but low pipeline creation indicates discovery and qualification. Each points to a different root cause and a different intervention.

Question 7

I am about to hire a VP Sales. Should I run a diagnosis first?

Accepted Answer

Yes. This is one of the highest-value applications of the GTM Risk Assessment. A VP Sales hired into a motion that has not been validated will spend their first three months diagnosing the motion themselves, at $15,000 to $20,000 per month in salary. If their diagnosis matches Wiremap's findings, you have paid $45,000 to $60,000 for a diagnosis you could have had for $999 in 7 days. If their diagnosis differs from what the motion actually needs, you have a significantly more expensive problem. What Wiremap produces before a VP Sales hire: a specific brief for what the motion needs, the ICP definition, the validated channel, the message architecture, the conversion benchmarks by stage, and the specific commercial gaps the hire needs to address. A VP Sales who walks in on day one with that brief can start executing immediately instead of spending three months in discovery.

Question 8

I have revenue but my pipeline is stalling. What will Wiremap tell me that I do not already know?

Accepted Answer

You already know something is wrong. What you probably do not know is whether it is an ICP problem, a messaging problem, a channel problem, a process problem, or a team execution problem, and in which order fixing them matters. The GTM Risk Assessment captures your current motion in detail. The finding identifies the root cause, the single problem whose resolution would move all the other numbers simultaneously. The most expensive mistake at growth stage is treating a direction problem as an execution problem. Adding volume, adding SDRs, or adding tools to a motion that is pointing at the wrong ICP with the wrong message produces faster failure, not more pipeline.

Question 9

We are expanding to a new geography. Can Wiremap help with this specifically?

Accepted Answer

Geography expansion is one of the highest-risk GTM decisions a B2B company makes and one of the most common applications of the GTM Risk Assessment. The specific risk: the motion that built the business in the current market will not necessarily transfer, and founders almost universally underestimate the degree to which it will not. The diagnosis examines whether the ICP transfers across markets, whether the trigger events and urgency signals are consistent, whether the channel that works domestically is the right channel in the target market, whether pricing benchmarks correctly against local competitors, and what social proof you need to establish credibility where you have no existing reference clients. The finding is not always do not expand. Frequently it is expand, but start with these specific sub-segments in this geography before attempting to replicate the full domestic motion.

Question 10

How is this different from the GTM tools I already use?

Accepted Answer

Apollo, Clay, Sales Navigator, Salesloft, and every outreach and intent tool in your stack execute your direction. Wiremap gives you the direction. Every outbound tool assumes your ICP is right, your positioning is validated, and your channel is the correct one. If any of those assumptions are wrong, those tools make a broken motion more efficient, not more effective. Wiremap operates before execution. It validates the direction before the execution tools deploy against it. When the direction is right, every tool in your stack produces better results. Wiremap is not a competitor to the tools you use. It is the prerequisite for those tools producing their maximum value.

Question 11

Why should our accelerator embed Wiremap in our programme?

Accepted Answer

Every company in your cohort is about to make a GTM decision that will cost them six months of runway if it goes wrong. The most common failure mode in early stage B2B companies is not bad product. It is ICP precision failure, positioning misalignment, and motion design errors that are diagnosable before the decision is made. Wiremap diagnoses that before it happens. The value to your programme: you add a structured GTM due diligence component that no other accelerator offers. Your founders receive a specific written diagnosis they can act on in the week they receive it. The outcome reflects on your programme quality and on the commercial maturity of your cohort. The structure is straightforward: cohort rate per company, co-branded reports under your programme name and Wiremap jointly, and an anonymised aggregate intelligence summary showing the most common GTM failure modes across your cohort, useful for tailoring programme content to where the real gaps are.

Question 12

How does Wiremap support portfolio companies from an investor perspective?

Accepted Answer

Portfolio companies making expensive GTM decisions without a diagnostic layer are a write-down risk. A VP Sales hire that fails in the first two quarters because the motion was never validated costs more than the salary. A demand gen investment that runs for six months before anyone diagnoses that the ICP is wrong costs more than the agency fee. Wiremap's GTM Risk Assessment at $999 before any of those decisions is the cheapest portfolio protection available. For VC partners with five or more portfolio companies, a quarterly anonymised intelligence report showing aggregate GTM failure patterns across the portfolio is available. This shows where to focus portfolio support resources and which companies are at highest commercial risk before the risk manifests as a pipeline problem.

Question 13

What makes this defensible as a business? What stops a well-funded competitor from replicating it?

Accepted Answer

The defensibility is in the data, not the product. Every report delivered contributes to a proprietary dataset that no competitor can access without also delivering the reports and tracking the outcomes. That dataset trains the intelligence engine being built in parallel with the diagnostic product. A competitor starting today faces a specific problem: they need the intake data, the outcome tracking data, and the validated pattern library to produce comparable findings. Building those three simultaneously requires the commercial operation, the intake instrument, and the outcome discipline all running in parallel. That is a three to five year head start that no amount of capital can shortcut, because the data has to be earned through delivered reports, not purchased. The category ownership play adds to this: the company that names and defines a category holds a first-mover position that followers cannot easily dislodge regardless of budget.

Question 14

What is the longer-term vision beyond the current diagnostic products?

Accepted Answer

The diagnostic product is the foundation. What is being built in parallel is a proprietary commercial intelligence engine trained on the intake data, the validated findings, and the outcome signals from every engagement delivered. At scale, this becomes a platform that provides continuous GTM monitoring, buying window intelligence from real-time market signals, and performance benchmarking against the highest-performing companies in the same segment. The category being created is commercial intelligence infrastructure: the layer that sits underneath every GTM tool, every sales engagement platform, and every intent signal service, and validates whether the direction all of those tools are executing against is actually correct. No company owns that layer today. That is the space Wiremap is building toward.

Question 15

What happens after I pay?

Accepted Answer

Within 30 minutes you receive an email from amulya@wiremap.co with your intake form link. The form takes 25 to 60 minutes depending on which product you have purchased, and you have 14 to 30 days to complete it at your own pace. Once you submit, your report is delivered within 7 business days for the GTM Clarity and Risk Assessments, and 10 business days for Revenue Due Diligence. The report arrives by email with a summary of the primary finding. The door remains open for follow-up questions via email on any specific finding.

Question 16

Will this tell me something I do not already know?

Accepted Answer

Yes, and that is the point. Every founder who goes through the intake believes they know what the problem is. The findings consistently identify a different root cause. Not because founders are wrong about the symptoms. Because symptoms and causes are different things, and the pattern recognition identifies which cause is producing which symptom. That identification is almost always not what the founder assumed. The most valuable reports are the ones that reframe the problem before the founder has committed more to solving the wrong version of it.

Question 17

What if I act on the recommendations and they do not work?

Accepted Answer

Wiremap delivers a diagnosis. What happens after depends on how it is executed. What Wiremap guarantees: every finding is specific to your company and passes a root cause validation test before it appears in the report. Every finding is practitioner reviewed before delivery. If the report is not delivered within the stated window due to a failure on Wiremap's side, the engagement is refunded. What Wiremap does not guarantee: commercial outcomes. No honest diagnostic service does. The diagnosis gives you the best possible starting point. The execution is yours.

Question 18

Should I run a Wiremap diagnosis more than once?

Accepted Answer

Yes. The founders who get the most from Wiremap treat it as a recurring practice rather than a one-time purchase. Every time something significant changes, a new hire, a new market, a product pivot, a drop in conversion, the motion that was working can quietly stop working. The diagnosis catches drift before it becomes a crisis. At early stage, run a GTM Clarity Assessment every time your direction changes significantly. At growth stage, a GTM Risk Assessment before any major commercial commitment. At scale, a Revenue Due Diligence as a standard part of fundraising preparation. Each report is independent and complete. You do not need to have run a previous report to get full value from the next one.

Question 19

Why is introductory pricing available and how long will it last?

Accepted Answer

Wiremap was deliberately launched at a price point that removes the friction from running a diagnosis before a major commercial decision. The belief behind it: founders should not need a $10,000 consulting engagement to find out what is actually limiting their revenue engine. Introductory pricing reflects that belief. The listed prices on wiremap.co — $499, $999, and $2,499 — are the current prices. There is no subscription, no retainer, and no ongoing commitment. You pay once for one assessment.

What you get	GTM Clarity $499 · 7 days	Growth Risk $499 · 7 days	GTM Risk $999 · 7 days	Revenue Expansion $999 · 7 days	Revenue DD $2,499 · 10 days
Best for	Pre-rev to $300K ARR. Building first motion.	Seed stage. Traction exists. Series A in 6–12 months.	$200K–$2M ARR. Hire, scale, or expand soon.	$500K–$2M ARR. NRR below 100%.	Series A or B prep. 60–90 days from raise.
ICP and buyer analysis	✅ Full	✅ Full	✅ Full	⚡ Expansion focus	✅ Investor grade
Positioning diagnosis	✅	✅	✅	—	✅
Constraint map (primary, secondary, emerging)	✅	✅	✅	✅	✅
Leadership readiness review	—	—	✅	✅	✅ Full + hire readiness
Cost of inaction (6 and 12 months)	✅	✅	✅	✅	✅ Investor framing
Revenue expansion analysis	—	—	—	✅ Full NRR analysis	✅
Investor-grade commercial narrative	—	—	—	—	✅ Investor-grade only
Scale readiness and repeatability score	—	—	✅ Is the motion ready?	—	✅
CEO board slide	✅	✅	✅	✅	✅
⚠ Not included	Scale readiness NRR analysis Leadership review	Revenue expansion Investor narrative Full leadership review	NRR deep dive Investor narrative Fundraise framing	Full ICP rebuild Positioning audit Scale readiness	Nothing — this is the most complete assessment
Start here →	Run GTM Clarity →	Run Growth Risk →	Run GTM Risk →	Run Rev Expansion →	Run Revenue DD →

Most companies don't fail
because they execute poorly.
They fail because they scale the wrong assumption.

Wiremap serves every stage of the growth journey.

Why smart companies still miss it.

The constraint is rarely where people are looking.

How Wiremap generates intelligence.

Wiremap adapts to where you are and where you are going next.

Good execution.
Wrong direction.

What you receive.

Which intelligence is right for you?

What the diagnosis actually finds

What Wiremap is not.

Four steps. No calls required.

Intelligence for every role in the growth ecosystem.

The patterns behind why GTM motions fail
and what actually fixes them

Everything you need to know

Built to compound intelligence over time.

Before you make the next expensive decision.

Most companies don't failbecause they execute poorly. They fail because they scale the wrong assumption.